Plantier J L, Rodriguez M H, Enjolras N, Attali O, Négrier C
INSERM U331, Laboratoire d'Hemobiologie-Faculté de Médecine RTH Laënnec, Lyon, France.
Thromb Haemost. 2001 Aug;86(2):596-603.
The biosynthesis of coagulation factor VIII (FVIII) is hampered by successive controls that limit its production. To improve this production, a truncated intron I sequence of factor IX (TFIXI1) was inserted in FVIII cDNA in place of FVIII introns 1, 12 and 13 and also as a combination between introns 1 and 12, and introns 1 and 13. The intron 12 and 13 locations were targeted because this region was previously shown to contain a transcriptional silencer. The expression of FVIII in CHO and HepG2 cells revealed important variations in the properties of the minigenes depending on the TFIXI1 insertion sites. In FVIII intron 13 location the TFIXI1 seemed to diminish the transcriptional silencer activity, whereas it was poorly spliced in intron 12 position. Among the five constructs, FVIII I1+13 leaded to a significant improvement in FVIII secretion (13 times) that was associated with a dramatic intracellular accumulation in cells. Therefore, the FVIII I1+13 minigene could represent a particular interest to produce recombinant FVIII in vitro as well as in the aim of gene therapy of haemophilia A.
凝血因子VIII(FVIII)的生物合成受到限制其产生的一系列调控的阻碍。为了提高其产量,将截短的因子IX内含子I序列(TFIXI1)插入FVIII cDNA中,取代FVIII的内含子1、12和13,也作为内含子1和12之间以及内含子1和13之间的组合。选择内含子12和13的位置作为靶点,是因为该区域先前已被证明含有转录沉默子。FVIII在CHO和HepG2细胞中的表达显示,根据TFIXI1的插入位点不同,小基因的特性存在重要差异。在FVIII内含子13位置,TFIXI1似乎降低了转录沉默子活性,而在其插入内含子12位置时,剪接效果较差。在这五个构建体中,FVIII I1+13导致FVIII分泌显著改善(提高了13倍),这与细胞内大量积累有关。因此,FVIII I1+13小基因对于体外生产重组FVIII以及用于A型血友病的基因治疗可能具有特别的意义。